| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |